FATE THERAPEUTICS INC Retained Earnings
FATE THERAPEUTICS INC (FATE) had Retained Earnings of -$1.60 billion as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.60B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.57B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.53B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.50B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.60B 10-Q · filed 2026-08-13 |
| 2026-03-31 | -$1.57B 10-Q · filed 2026-05-13 |
| 2025-12-31 | -$1.53B 10-Q · filed 2026-08-13 |
| 2025-09-30 | -$1.50B 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$1.47B 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$1.44B 10-Q · filed 2025-05-13 |
| 2024-12-31 | -$1.40B 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.35B 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$1.30B 10-Q · filed 2024-08-13 |
| 2024-03-31 | -$1.26B 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$1.21B 10-K · filed 2025-03-05 |
| 2023-09-30 | -$1.17B 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$1.12B 10-Q · filed 2023-08-08 |
| 2023-03-31 | -$1.07B 10-Q · filed 2023-05-03 |
| 2022-12-31 | -$1.05B 10-K · filed 2024-02-26 |
| 2022-09-30 | -$994.44M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$910.88M 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$834.77M 10-Q · filed 2022-05-04 |
| 2021-12-31 | -$769.08M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$700.46M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$657.15M 10-Q · filed 2021-08-04 |
| 2021-03-31 | -$602.02M 10-Q · filed 2021-05-05 |
| 2020-12-31 | -$556.93M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$503.82M 10-Q · filed 2020-11-05 |
| 2020-06-30 | -$445.14M 10-Q · filed 2020-08-05 |
| 2020-03-31 | -$417.06M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$383.55M 10-K · filed 2021-02-24 |
| 2019-09-30 | -$355.24M 10-Q · filed 2019-11-05 |
| 2019-06-30 | -$328.63M 10-Q · filed 2019-08-06 |
| 2019-03-31 | -$305.16M 10-Q · filed 2019-05-07 |
| 2018-12-31 | -$285.40M 10-K · filed 2020-03-02 |
| 2018-09-30 | -$269.37M 10-Q · filed 2018-11-01 |
| 2018-06-30 | -$252.59M 10-Q · filed 2018-08-06 |
| 2018-03-31 | -$232.93M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$218.80M 10-K · filed 2019-03-05 |
| 2017-09-30 | -$206.30M 10-Q · filed 2017-11-01 |
| 2017-06-30 | -$195.62M 10-Q · filed 2017-08-14 |
| 2017-03-31 | -$185.97M 10-Q · filed 2017-05-15 |
| 2016-12-31 | -$175.85M 10-K · filed 2018-03-05 |
| 2016-09-30 | -$167.91M 10-Q · filed 2016-11-07 |
| 2016-06-30 | -$159.17M 10-Q · filed 2016-08-08 |
| 2016-03-31 | -$150.76M 10-Q · filed 2016-05-09 |
| 2015-12-31 | -$142.38M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$134.94M 10-Q · filed 2015-11-03 |
| 2015-06-30 | -$128.05M 10-Q · filed 2015-08-05 |
| 2015-03-31 | -$120.27M 10-Q · filed 2015-05-07 |
| 2014-12-31 | -$112.39M 10-K · filed 2016-03-03 |
| 2014-09-30 | -$106.16M 10-Q · filed 2014-11-12 |
| 2014-06-30 | -$99.56M 10-Q · filed 2014-08-12 |
| 2013-12-31 | -$86.51M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |